Thursday 5th April 2018
|Text too small?|
Synlait Milk said it will spend about $18 million to double production of lactoferrin at its Dunsandel plant after securing a multi-year agreement to supply the high-value milk protein.
The dairy company didn't identify the customer but said a demand and supply imbalance "is driving global strengthening of lactoferrin prices and demand is notably driven from increasing use of lactoferrin in infant formula, particularly in China." It expects to complete the expansion by October.
"As a specialty ingredient, lactoferrin commands a much higher price per metric tonne than many other dairy-based ingredients," said Elizabeth Reid, a group category manager at Synlait, in a statement.
Last year Synlait gained a GRAS (Generally Recognised As Safe) notice from the US Food and Drug Administration to export lactoferrin to the US for use in infant formula and toddler formula, saying at the time it was only the second company worldwide to get that status.
The company is coy about the financial details of its lactoferrin business. Its 2017 annual report says it sold 11 metric tonnes of the iron-binding protein last year, up from 10 tonnes in 2016. According to Synlait, the specialty ingredient is recognised for its anti-bacterial and anti-inflammatory properties.
Last month, Synlait posted a record first-half profit of $40.7 million, which it attributed to production and sales of high-margin products and its partnership with A2 Milk.
Synlait shares rose 2 percent to $9.13 and have soared 169 percent in the past 12 months.
No comments yet
NZ dollar falls with Aussie after Westpac's RBA rate cut call
Intuit juggernaut grows QuickBooks subscribers but momentum slows
Reaction to Budget rules relaxation shows balance 'about right', says Ardern
Augusta lifts net profit six fold as investors flock into new funds
Annual exports to China top $15 billion for first time
Gentrack posts $8.7M loss on CA Plus write-down
Westpac says RBNZ capital proposals would add $6,000 p.a. to an Auckland mortgage
Cavalier says market conditions still challenging
Ryman hikes dividend as annual earnings grow on wider development margin
24th May 2019 Morning Report